In partnership with
The Wednesday Reset — A weekly mental-health edition from AIHealthTech Insider
Weight-loss drugs are entering a new stage of research. A Phase 3 trial has reported early results in children ages 6–11, raising questions that extend beyond BMI to growth, body image and long-term well-being.
This is a tender subject for many of us — especially anyone who's navigated their own relationship with weight, food, or body image. We've covered it carefully, and there are support resources included below. 🌿
— Issue #019
A note from your AIHealthTech Insider team: every Monday we cover AI in healthcare. Every Wednesday, the human side — the part no algorithm can fix alone. This is that edition.
Quick question before we dive in 👇
When treating childhood obesity, what deserves the most attention?
The Big Story
Wegovy Shows Early Results in Children Ages 6–11
Novo Nordisk released the first results from STEP Young, a Phase 3 trial of 165 children ages 6–11 with obesity.
Children received weekly semaglutide or placebo for 68 weeks alongside diet and physical-activity support.
Among participants assumed to have followed treatment, 40.4% of those receiving semaglutide were no longer classified as having obesity, compared with none receiving placebo.
More than 85% began with severe obesity. Novo Nordisk reported no new safety concerns involving growth or puberty.
The honest part: These are company-reported topline results, not a peer-reviewed paper. Average BMI change, adverse-event and discontinuation data, and psychological outcomes remain unavailable. Full results are due at ObesityWeek in November.
Another Study to Know
Prescribing Was Already Rising Before the Trial Results
A new Pediatrics study examined records from 3.5 million U.S. children ages 8–11 with obesity and without diabetes.
Researchers identified 20,282 children who received a GLP-1 prescription. Annual prescribing rose sharply but remained uncommon at approximately 0.6%.
Of those prescribed treatment, 93.7% had severe obesity and 65.2% had a related health condition. Prescribing was more likely in less socioeconomically vulnerable communities.
Why it matters: Treatment appears concentrated among high-risk children, but access may be unequal.
The limitation: Records show prescriptions—not sustained use or long-term outcomes.
💚 Sponsor
It's Here: Pique's New Caffeine-Free Afternoon Energy
I quit my afternoon coffee. Not because I wanted to — because I found something better.
You know that wall you hit every day around 2–3 PM? I used to just accept it as the cost of doing anything. Another coffee, a quick spike, then the crash — and somehow I'd still feel dehydrated by dinner.
Then I tried X·E Fountain, Pique's brand-new electrolyte energy drink, and I genuinely wasn't ready for how good "no crash" could feel.
No caffeine jitters. No 4 PM slump. Just clean, steady energy that actually hydrates me instead of draining me. It's built with a premium Vitamin B Complex for natural cellular energy, Magnesium Malate + Taurate for real focus, and a full electrolyte blend that makes it feel like a treat, not a chore.
The cucumber-celery-lime flavor is so crisp and refreshing — it's basically stolen my afternoon coffee slot completely.
The Mental-Health Question
A Lower BMI Does Not Automatically Mean Better Well-Being
A 2026 review combined 33 longitudinal studies of weight and mental well-being in young people.
Higher childhood weight was associated with poorer later well-being, although findings varied substantially. The relationship might also work in both directions.
Some evidence suggested that body dissatisfaction and perceived weight may matter more for later well-being than measured weight alone.
Future pediatric trials therefore need to measure self-esteem, body image, eating behavior and quality of life—not only BMI.
The AI Angle
Can AI Predict Which Patients Will Respond?
A 2026 study used NIH All of Us data to predict GLP-1 outcomes with machine learning. It included 11,420 adults for weight outcomes and 3,975 for blood-sugar outcomes.
The models could support more personalized treatment, but the study was retrospective and adult-only. They cannot guide pediatric treatment without prospective validation.
💚 Sponsor
Get 15% Off Coffee Pods Roasted Days Ago
Angelino's roasts, grinds, and seals 50+ specialty coffees in-house at their LA roastery, then ships within days. Mix and match to unlock up to 34% off — and new customers get 15% off on top, applied automatically. No code, no subscription required.
Connection in Action
Support for Healthier Conversations About Weight
Conversations about weight can affect body image and a person’s relationship with food. ANAD offers free peer support for anyone experiencing eating-disorder or body-image concerns. A diagnosis is not required.
Mental Wellness — Coming Up
October 14 — Treating Eating Disorders Without Weight Bias
Psychologist Lauren Mulheim and adolescent-medicine specialist Rebecka Peebles will introduce CBT-WI, an approach intended to address eating disorders without reinforcing weight bias.
In Case You Missed It
Why an Entire Generation Is Losing Close Friends
Last week: what the friendship decline means—and what communities are doing about it.
The Reset
Treating a child is not simply a smaller version of treating an adult.
The question is not only whether medication changes BMI, but whether children grow safely and experience better long-term well-being.
Until next Wednesday. 🌿
Know a parent, clinician or educator following this conversation? Share this careful breakdown with them.
Want Monday’s AI-health briefing but not The Wednesday Reset? Update your preferences below and stay subscribed to AIHealthTech Insider.
